Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer.

MLA

Plumber, Sakina A., et al. “Rosiglitazone and Trametinib Exhibit Potent Anti-Tumor Activity in a Mouse Model of Muscle Invasive Bladder Cancer.” Nature Communications, vol. 15, no. 1, Aug. 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1038/s41467-024-50678-2.

APA

Plumber, S. A., Tate, T., Al-Ahmadie, H., Chen, X., Choi, W., Basar, M., Lu, C., Viny, A., Batourina, E., Li, J., Gretarsson, K., Alija, B., Molotkov, A., Wiessner, G., Lee, B. H. L., McKiernan, J., McConkey, D. J., Dinney, C., Czerniak, B., & Mendelsohn, C. L. (2024). Rosiglitazone and trametinib exhibit potent anti-tumor activity in a mouse model of muscle invasive bladder cancer. Nature Communications, 15(1), 1–16. https://doi.org/10.1038/s41467-024-50678-2

Chicago

Plumber, Sakina A., Tiffany Tate, Hikmat Al-Ahmadie, Xiao Chen, Woonyoung Choi, Merve Basar, Chao Lu, et al. 2024. “Rosiglitazone and Trametinib Exhibit Potent Anti-Tumor Activity in a Mouse Model of Muscle Invasive Bladder Cancer.” Nature Communications 15 (1): 1–16. doi:10.1038/s41467-024-50678-2.